KMT5C

Histone-lysine N-methyltransferase KMT5C

2,788 patent compounds predicted against KMT5C, 2,221 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1613404	0.81	2/20
SCHEMBL4963680	0.80	2/20
SCHEMBL1147527	0.78	2/20
SCHEMBL3706336	0.78	2/20
SCHEMBL3708467	0.78	2/20
SCHEMBL3711288	0.78	2/20
SCHEMBL4811736	0.78	2/20
SCHEMBL6861746	0.78	2/20
SCHEMBL6861753	0.78	2/20
SCHEMBL1147688	0.76	2/20
Hydrochloric Acid (SCHEMBL1876988)	0.76	2/20
SCHEMBL6865829	0.76	2/20
SCHEMBL6865834	0.76	2/20
SCHEMBL1147609	0.74	2/20
SCHEMBL4810793	0.71	2/20
SCHEMBL1147647	0.71	2/20
SCHEMBL1550555	0.71	2/20
SCHEMBL3711092	0.70	2/20
SCHEMBL6866156	0.70	2/20
SCHEMBL6866164	0.70	2/20

Germline variants in KMT5C on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full KMT5C gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to KMT5C by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia	PHASE2	RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas	PHASE1/PHASE2	UNKNOWN
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab	PHASE1/PHASE2	RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors	PHASE1/PHASE2	RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias	PHASE1	WITHDRAWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma	PHASE1	ACTIVE_NOT_RECRUITING
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors	PHASE1	RECRUITING
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	PHASE1	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders	nan	COMPLETED
Mechanisms of Immune Deficiency	nan	UNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia	nan	COMPLETED
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome	nan	UNKNOWN
The Crosstalk Between the Epigenome and Mitochondria in SCI	nan	NOT_YET_RECRUITING
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
Liquid Biopsy in Germ Cell Tumors	nan	NOT_YET_RECRUITING
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer	nan	UNKNOWN
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System	nan	UNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19	nan	COMPLETED
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a KMT5C binder may also engage these)

Protein	Name	Similarity
P0C2N6	—	0.995	P0C2N6 →
Q6Q783	—	0.994	Q6Q783 →
MAP3K10	Mitogen-activated protein kinase kinase kinase 10	0.983	landscape →
Q8BQU6	—	0.982	Q8BQU6 →
Q76KP1	—	0.981	Q76KP1 →
D3ZG83	—	0.981	D3ZG83 →
LMTK3	Serine/threonine-protein kinase LMTK3	0.980	landscape →
A2A699	—	0.980	A2A699 →
A2AEV7	—	0.980	A2AEV7 →
Q7TN12	—	0.980	Q7TN12 →
Q29RK8	—	0.980	Q29RK8 →
TESK1	Dual specificity testis-specific protein kinase 1	0.980	landscape →
Q2M3V2	—	0.979	Q2M3V2 →
A8MVW0	—	0.979	A8MVW0 →
Q566C8	—	0.979	Q566C8 →
O43900	—	0.979	O43900 →
O43918	—	0.979	O43918 →
O94761	—	0.979	O94761 →
Q96FS4	—	0.979	Q96FS4 →
E1BEA8	—	0.978	E1BEA8 →
Q66HA1	—	0.978	Q66HA1 →
Q80XI6	—	0.978	Q80XI6 →
Q8BY98	—	0.978	Q8BY98 →
Q8BLS7	—	0.978	Q8BLS7 →
Q9Z0E3	—	0.978	Q9Z0E3 →
Q9H6W3	—	0.978	Q9H6W3 →
Q5T442	—	0.978	Q5T442 →
A6NIN4	—	0.978	A6NIN4 →
Q9Z188	—	0.978	Q9Z188 →
Q9UQQ2	—	0.977	Q9UQQ2 →